Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment

摘要

Epidermal growth factor receptor tyrosine kinaseinhibitors (EGFR-TKIs) haveachieved remarkableclinicalresponses in advanced non-small-cell lung cancer (NSCLC) patients harboring activatingEGFRmutations. [1–3] Lung adenocarcinoma patients withEGFRmutations had aresponse rateas high as 80%to EGFR-TKI treatmentand approximately 9 to 13 months of progression-freesurvival(PFS).